Drug Repurposing to find Inhibitors of SARS-CoV-2 Main Protease by Angelina, Emilio et al.
DRUG REPURPOSING TO FIND INHIBITORS OF SARS-CoV-2 MAIN PROTEASE 
 
Emilio Angelina​a)​ , Sebastian Andujar​b)​, Oscar Parravicini​b)​, Daniel Enriz​b)​ and Nelida Peruchena​a)  
 
a)​Lab. Estructura Molecular y Propiedades, IQUIBA-NEA, Universidad Nacional del Nordeste, 
CONICET, FACENA, Av. Libertad 5470, Corrientes 3400, Argentina 
b)​Instituto Multidisciplinario de Investigaciones Biológicas (IMIBIO-SL), CONICET, San Luis, Argentina 
 
 
ABSTRACT  
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus 
that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the 
COVID-19 pandemic. Currently there is no known vaccine or specific antiviral treatment for 
COVID-19 and so, there is an urgent need for expedite discovery of new therapeutics to 
combat the disease until a vaccine will be available worldwide.  
Drug repurposing is a strategy for identifying new uses for approved drugs that has the 
advantage (over conventional approaches that attempt to develop a drug from scratch) that 
time frame of the overall process can be significantly reduced because of the few number of 
clinical trial required.  
In this work, a virtual screening of FDA-approved drugs was performed for repositioning as 
potential inhibitors of the main protease M​pro​ of SARS-CoV-2. As a result of this study, 12 
drugs are proposed as candidates for inhibitors of the M​pro​ enzyme. Some of the selected 
compounds are antiviral drugs that are already being tested in COVID-19 clinical trials (i.e. 
ribavirin) or are used to alleviate symptoms of the disease (i.e. codeine). Surprisingly, the 
most promising candidate is the naturally occurring broad spectrum antibiotic 
oxytetracycline. This compound has largely outperformed the remaining selected candidates 
along all filtering steps of our virtual screening protocol.  
If the activity of any of these drugs is experimentally corroborated, they could be used 
directly in clinical trials without the need for pre-clinical testing or safety evaluation since they 
are already used as drugs for other diseases. 
 
INTRODUCTION 
Coronavirus disease 2019 (COVID-19) is the disease caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.​[1]​ It has named so because its 
RNA genome is about 82% identical to that of the SARS coronavirus (SARS-CoV).​[2]  
The World Health Organization (WHO) declared the 2019-20 coronavirus outbreak a Public 
Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemy on 
11 March 2020.​[3]​ As of 15th May 2020 SARS-CoV-2 has caused more than four million of 
infections all around the globe and more than three hundred thousand deaths. 
Currently, there is no vaccine or specific antiviral treatment for COVID-19.​[4]​ Therefore, there 
is an urgent need, today more than ever before, for expedite discovery of novel therapeutics.  
Since the process of bringing a new pharmaceutical drug to the market, once a lead 
compound has been identified, usually takes from 10-15 years, a workaround to shorten the 
drug discovery cycle is required in the current scenario.  
Drug repurposing or repositioning is a strategy for identifying new uses for approved drugs 
that are outside the scope of the original medical indication.​[5]​ This strategy offers various 
advantages over developing an entirely new drug for a given indication. The most relevant 
one in the context of the current COVID-19 pandemy is the time frame for drug development 
that can be significantly reduced because most of the preclinical testing, safety assessment 
and formulation development already have been completed.  
Moreover, since the onset of COVID-19 outbreak in Wuhan in December 2019, a lot of 
scientific resources related to SARS-CoV-2 have been released in expedited time, from the 
virus genome sequence​[2]​ to protein structures solved by X-Ray crystallography to 
supramolecular structures mapped at atomic scale by CryoEM,​[6, 7]​ which makes it possible 
to apply a Structure-based drug approach for drug discovery. 
In the Protein Data Bank there are currently deposited both structural proteins of 
SARS-CoV-2 like the spike glycoprotein (S) and also non-structural proteins (NSPs) like the 
main protease (M​pro​), papain-like protease (PL​pro​), RNA-dependent RNA polymerase (RdRp) 
among other NSPs.  
The S glycoprotein on the virion surface mediates receptor recognition and membrane fusion 
to gain entry into host cells. Biophysical and structural evidence reveal that both SARS-CoV 
and SARS-CoV-2 share the same functional host cell receptor, angiotensin-converting 
enzyme 2 (ACE2) but the novel strain binds to it with 10 to 20-fold higher affinity than the 
former which may contribute to the apparent ease with which SARS-CoV-2 can spread.​[7] 
Because of its indispensable function, it represents a target for antibody-mediated 
neutralization. However, for small molecule drug design, protein-protein interaction (PPI) 
surfaces like that in S-ACE2 complex is very difficult to target because of its large size and 
flatness. Compared to the active site of an enzyme, PPIs are stabilized through large 
interfaces and it has been considered a difficult task to find small molecules competing with 
the binding of a protein partner. ​[8]  
Regarding NSPs, RNA-dependent RNA polymerase (RdRp) is an enzyme required for 
SARS-CoV-2 replication and it was shown that can be inhibited by remdesivir, a broad 
spectrum antiviral drug that has been originally developed to treat Ebola virus disease.​[9]​ On 
29 April 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced 
that remdesivir was better than a placebo in reducing time to recovery for people 
hospitalized with advanced COVID-19 and lung involvement.​[10]​ Although remdesivir has now 
been authorized for emergency use in the U.S., it is far from being the “silver bullet” to cure 
COVID-19.  
Moreover, viral proteases are often druggable targets, HIV protease inhibitors are perhaps 
the most successful story about viral protease inhibitors development. Similarly to HIV 
protease, SARS-CoV-2 main protease (M​pro​) is essential for processing the polyproteins that 
are translated from the viral RNA. Therefore, inhibiting the activity of this enzyme would 
eventually stop viral replication.​[11]  
One of the treatments options currently under study as part of the solidarity trial launched by 
the WHO​[12]​ involves two HIV protease inhibitors, Lopinavir and Ritonavir. Regrettably, 
preliminary results conducted in adults hospitalized with severe COVID-19 has not shown 
benefit from this treatment.​[13]  
In this work we performed a Virtual Screening (VS) study for drug repurposing of FDA 
approved drugs as potential SARS-CoV-2 M​pro​ inhibitors. 
M​pro ​is a dimer of two identical subunits (Figure 1), with each protomer composed of three 
domains. Two antiparallel β-barrel structures conform domains I and II and a third globular 
α-helical domain III is connected to domain II by means of a long loop region.​[14]​ The 
substrate binding cleft is located between domains I and II.  
The fold of the first two domains resemble architecture of serine proteases like 
chymotrypsin, but a cysteine amino acid and a nearby histidine (catalytic dyad) perform the 
protein-cutting reaction. The third α-helical domain is involved in regulating the dimerization 
of M​pro​.​[11] 
 
Figure 1​. Structure M​pro​ (monomer A) in complex with potent α-ketoamide inhibitor 13b from reference 
11 (PDB code 6Y2G). 
 
  
Hilgenfeld and colleagues have recently designed and synthesized peptidomimetic 
α-ketoamides to be used as inhibitors of the main proteases of coronaviruses. They 
obtained a potent inhibitor of the SARS-CoV-2 M​pro​.​[11]​ In another study, Jin and colleagues 
identified a mechanism-based inhibitor, N3, by computer-aided drug design and 
subsequently determined the crystal structure of SARS-CoV-2 M​pro​ in complex with this 
compound.​[14]​ Solved structures of the enzyme in complex with these two potent 
peptidomimetic inhibitors (PDB accession codes 6Y2G and 6LU7, respectively) provides 
structural basis for design of novel drug-like inhibitors. Moreover, another recent 
crystallographic fragment screening against SARS-CoV-2 M​pro​ that has been deposited in 
the Protein Data Bank (DOI: ​10.2210/pdb5rgj/pdb​) also might help to find structural 
determinants for ligand anchoring within the enzyme binding cleft. In this work we exploited 
the available structural information about ligand binding to M​pro​ binding cleft to guide the drug 
repurposing Virtual Screening experiment. 
 
COMPUTATIONAL DETAILS  
Figure 2 shows the overall workflow for selection of candidate compounds.  
 
 
Figure 2​. Workflow of the Virtual Screening procedure for candidate compound selection.  
 
FDA-approved drugs collection compiled as 3D SDF files was downloaded from BindingDB 
database (​www.bindingdb.org​). LigPrep by Schrodinger was used to generate the different 
protomers and tautomers while retaining specified chiralities.​[15]​ After generating the different 
chemical possibilities, the drug repurposing library ended up with ~ 3000 compounds.  
Solved structure of unliganded form of SARS-CoV-2 M​pro​ was employed as receptor for rigid 
docking (accession code: 6YB7). Up to date, more than 100 structures of SARS-CoV-2 M​pro 
with ligands bound at the enzyme binding cleft, have been released. These ligand-bound 
structures of the enzyme were exploited in this work to find key interaction sites or “hot 
spots” within the binding cleft. These “hot spots” were then incorporated as pharmacophoric 
restraints (ph4s) to guide docking solutions.  
Docking of drug repurposing library was performed with rDock program.​[16]​ The cavity was 
prepared with the reference ligand method, using coordinates of inhibitor N3 covalently 
bound to SARS-CoV-2 M​pro​(accession code 6LU7). N3 is a large peptidomimetic inhibitor 
that target all the binding cleft sub-pockets. Structure of 6LU7 was  aligned to 6YB7 before 
performing the cavity mapping.  
For each docked ligand, poses were sorted by total SCORE from standard rDock scoring 
function (SF) and only the top ranked pose was kept. Then, ligands best poses were sorted 
based in SF terms that account for intermolecular interactions (SCORE.INTER) and 
satisfaction of pharmacophoric restraints (SCORE.RESTR), whenever applicable. Top 200 
ranked drugs (i.e. those that achieve the stronger interactions and satisfy the imposed 
restraints) were selected for DUck simulations (Figure 2).  
DUck is a fast protocol for Steered Molecular Dynamic (SMD) simulations that has been 
thought for using in drug discovery projects. DUck calculates the work necessary to reach a 
quasi-bound state at which the ligand has just broken the most important native contact with 
the receptor (W​QB​). Since true ligands form more resilient interactions than decoys, this 
non-equilibrium property has shown to be surprisingly effective in virtual screening 
contexts.​[17]  
To drive the DUck simulations we choose one of the “hot spots” identified in the previous 
PDB survey of available SARS-CoV-2 M​pro​ complexes, i.e. the sames that were also 
considered for defining the ph4 restraints to guide docking calculations (see results section). 
Those ligands requiring a W​QB​ > 4 kcal/mol to break the reference hydrogen bond with the 
enzyme were further scrutinized by MD simulations and binding free energy calculations.  
While DUck evaluates structural stability, binding free energy estimations provide information 
about thermodynamic stability of the complexes. Therefore, they are orthogonal to each 
other and can offer complementary information about complex stability. Accordingly, 
complexes that surpassed DUck filter were subjected to 20 nanoseconds of MD simulations 
in triplicate with Amber 16 software package (All-atoms force field ff14SB).​[18]​ Those MD 
trajectory replicas from which ligand did not detached from enzyme binding cleft were 
sampled at regular intervals to get an averaged estimate of the relative binding free energy 
(​ΔΔG​) of complexes by applying the MM-GBSA protocol. The details of this method have 
been presented elsewhere.​[19]​ The conformational entropy change −TΔS is usually computed 
by normal mode analysis, but in this study the entropy contributions were not calculated. In 
practice entropy contributions can be neglected when comparing states with similar entropy 
such as two ligands binding to the same protein, provided that only the relative free energy is 
informed.  
 
Quantum Theory of Atoms in Molecules (QTAIM) 
QTAIM analysis consists in the mapping of the gradient vector field ∇ on top of the charge 
density (ρ) of the system thus giving rise to the topological elements of the charge density, 
two of which are unequivocal indicators of a bonding interaction: the Bond Critical Point 
(BCP) and the Bond Paths (BPs) that connect BCP to the bonded atoms.​[20]​ Unlike the 
geometrical parameters (i.e. bond distance and angle and also types of atoms involved) for 
describing non covalent interactions, QTAIM does not rely on any arbitrary criteria for 
deciding whether an interaction is actually formed or not: the sole presence of a BCP and 
the corresponding BPs between two atoms guarantee the existence of the interaction.  
The electronic charge density for complexes of SARS-CoV-2 M​pro​ with selected candidate 
compounds was computed with Gaussian 16 software package.​[21]​ The topological analysis 
of the charge density was then carried out with the help of Multiwfn​[22] ​and ​in house​ python 
scripts. To sample a proper structure from the MD simulations for QTAIM analysis, trajectory 
frames were aligned by protein backbone atoms and then clusterized by similarity based on 
their Root Mean Square Deviations (RMSD). A representative structure from the most 
populated cluster was selected for QTAIM calculations.  Since quantum mechanical 
calculations are still forbidden for full biomolecular complexes, reduced model systems were 
constructed from the selected representative structures by considering residues up to a 
distance range of  5 Å from ligand atoms.  
 
RESULTS AND DISCUSSION  
Figure 3 shows fragments from a recent reported crystallographic fragment screening on 
SARS-CoV-2 M​pro​ (​10.2210/pdb5rgj/pdb​).  
 
Figure 3​. Fragments from a crystallographic fragment screening as they bound to M​pro​ binding cleft. 
As observed in figure inset at the bottom right corner, the binding cleft is composed of several 
sub-pockets. At the S1 sub-pocket, we noted two conserved hydrogen bond (H-bond) sites among 
fragments that involves Gly 143 – Ser 144 backbone and His 163 imidazole. Pharmacophoric 
restraints (cyan spheres) at these interaction sites were considered to guide docking solutions in VS 
campaigns.  
 
While different fragments bind to different regions of SARS-CoV-2 M​pro ​binding cleft, there 
are two interaction sites at the enzyme S1 sub-pocket that are targeted by most fragments. 
They involve His 163 imidazole  (site 1) and backbone of Gly 143 and Ser 144 residues from 
a loop structure that hold the catalytic Cys 145 (site 2). In both cases fragments are acting 
as H-bond acceptors against corresponding interaction site.  
Interaction site 2 is specialized to hold an H-bond acceptor, since main-chain amides of Gly 
143, Ser 144 and Cys 145 form the canonical “oxyanion hole” of the cysteine protease that 
stabilize the transition state negative charge on the amide carbonyl oxygen of the substrate 
after nucleophilic attack by Cys 145.​[11]  
Regarding interaction site 1, a closer look at His 163 neighborhood reveals that its 
interaction partner in most of the structures is not really one of the fragments from the 
crystallographic screen but it is actually a co-solvent molecule of DMSO. The fact that a 
DMSO molecule is almost constantly anchored at this site might indicate either that 
fragments do not have preference for it or that they are not able to displace the DMSO 
molecule. Solved structures of SARS-CoV-2 M​pro​ in complex with peptidomimetic inhibitors 
(PDBs 6Y2G and 6LU7) show that inhibitor  P1 𝛾-lactam moiety, designed as a glutamine 
surrogate, is deeply embedded in the S1 pocket of the protease where the lactam oxygen 
accept an H-bond from the imidazole of His 163.​[11]​ Therefore, it is likely that His 163 
interaction site is also important for ligand anchoring at the S1 sub-pocket.  
As these interaction sites or “hot spots” seem to be important for ligand binding we have 
taken them into account in the virtual screenings in the way of pharmacophoric restraints, a 
functionality of the docking algorithm that is useful to incorporate knowledge-based features 
to guide docking solutions.  
We first ran a virtual screening (VS) round without imposing pharmacophoric restraints and 
noted that most drugs tend to lay over the catalytic loop at the S1 sub-pocket forming 
H-bonds with backbone of Gly 143 and/or Ser144. Therefore, a restraint to force formation of 
these interactions might not be necessary in most cases. Nevertheless, to ensure anchoring 
on the catalytic loop, an H-bond acceptor restraint was set close to Gly 143 backbone (site). 
A gentle tolerance radius of 1.0 Å was asigned so that the ligand acceptor atom can satisfy 
the restraint by H-bonding to either Gly 143 N-H bond or any of the nearby equivalent bonds 
from the catalytic loop backbone (i.e. from Ser 144 or even Cys 145).  
On the other hand, H-bond interaction with His 163 imidazole (site 1) was less frequently 
observed among docking poses and so, a restraint at this interaction site is mandatory to 
force H-bond formation. Accordingly, a second round of VS was run with pharmacophoric 
restraints at both interaction sites.  
Top ranked compounds from both VS rounds were further scrutinized with methodology that 
allow a more accurate characterization of the binding event. Compounds that surpassed 
docking filters (see computational details section) were first subjected to DUck calculations. 
For compounds selected from the first unrestrained VS run, interaction site 2 was chosen to 
drive DUck calculations since H-bond to site 1 was rarely observed without imposing 
restraints, as discussed above. Whereas for compounds filtered from the second restrained 
VS round, both interaction sites were considered for W​QB​ calculation and the highest value is 
informed (see Table 1 notes).  
Standard MD simulations were then carried out in triplicate for compounds that performed 
well in DUck calculations in order to get an estimate of their relative binding energies (ΔΔG) 
to M​pro​ protease.  For comparison purposes, binding energy was also computed for potent 
alpha-ketoamide inhibitor of SARS-CoV-2 M​pro​ previously co-crystallized with the enzyme 
(accession code 6Y2G).  
Table 1 reports candidate compounds selected from both VS rounds according to the 
protocol described in Figure 2.  And figure 4 shows best docking poses of selected inhibitors 
from Table 1.  
 
 
 
 
Table 1​. Candidates compounds selected for experimental testing as non-covalent          
SARS-CoV-2 M​pro​ inhibitors.  
      
Drug name rDock Rank W​QB​a),b) Pose stability?​ ​c),e) ΔΔG​ ​a),d),e) VS run 
Codeine (COD) 7 4.01​(s1) yes (2/3) 30.34 restrained 
Ticagrelor (TIC) 11 4.44​(s2) NC NC restrained 
Oxytetracycline ​(OTC) 12 11.18​(s2) yes (3/3) 12.39 unrestrained 
Ribavirin (RIBA) 14 4.70​(s1) yes (2/3) 39.25 restrained 
Chlortetracycline 16 4.75​(s2) NC NC unrestrained 
Losartan 16 4.66​(s1) NC NC restrained 
Doxycycline 20 4.16​(s2) NC NC unrestrained 
Dyphylline 29 4.33​(s1) NC NC restrained 
Regadenoson 62 4.80​(s2) NC NC unrestrained 
Etoposide 108 4.40​(s2) NC NC unrestrained 
Pentostatin (ECF) 163 8.02​(s2) NC NC unrestrained 
Elvitegravir (ELV) 171 6.75​(s2) NC NC unrestrained 
a) In kcal/mol 
b) W​QB​ value necessary to break ligand interaction with site 1 or 2 as indicated by the labels (s1) or (s2).  
c) A pose is considered to be stable if ligand remains attached to binding cleft during simulation in at least 1 of 3 
replicas.  
d) ΔΔG was computed with respect to potent 𝛼-ketoamide inhibitor. 
e) NC = Not Computed yet 
 
Figure 4​. Docking poses for selected compounds from Table 1. COD = codeine, TIC = ticagrelor, 
OTC = oxytetracycline, RIBA = ribavirin, ECF = pentostatin, ELV = elvitegravir.  
 
 
Compounds in Figure 3 can be considered as a representative sample of common scaffolds 
found among top ranked compounds from both VS rounds.  
COD, ELV and OTC, despite having different overall structure they share a common 
pharmacophoric feature consisting in two acceptor oxygen atoms in a planar structure at 
3-bonds distance to each other (i.e. in 1, 4 position). This acceptors disposition allows 
formation of several N–H···O interactions with H-bond donors from the catalytic loop 
backbone, at the S1 sub-pocket. At least one of the acceptor atoms is involved in a ring 
structure which is oriented nearly perpendicularly to the catalytic loop and flanked at both 
sides by side chain of Cys 145 and Asn 142.  
On the other hand, nitrogen-rich heterocyclic rings from RIBA, TIC and ECF also tend to 
interact with the oxyanion hole donors but they are oriented parallel to the catalytic loop 
backbone forming N–H···𝝅 interactions.  
In addition to binding at the catalytic loop, additional anchoring to S1 sub-pocket is provided 
by interactions with side chain of His 163, Ser 144 and Glu 166 and backbone of Phe 140. 
Anchoring at this deepest region of S1 sub-pocket seems to be better achieved by 
compounds having a 5-membered sugar-like ring placed at this region (i.e. as in RIBA, ECF 
and TIC) that is able to form an extensive H-bond network through its OH groups.  
Moreover, TIC, ECF and EVG also target S1’ sub-pocket, the first two compounds form a 
strong N–H···O interaction with backbone carbonyl oxygen of residue Thr 26 from such 
sub-pocket.  
Most compounds do not extend beyond S1 and S1’ sub-pockets except OTC that also target 
S2 and S3 sub-pockets from enzyme binding cleft by forming two strong interactions with 
backbone of Glu 166, among other interactions (discussed below). COD and TIC partially 
extend into S2 sub-pocket by accepting a proton from backbone amide of Glu 166.  
Regarding the known uses of these drugs, COD is already being used for clinical 
management of COVID-19 patients to suppress coughing when it is distressing. It could be 
the case that a therapeutic effect of COD (i.e. due to M​pro​ inhibition) might be also operating 
under the hood in conjunction with its cough alleviating effect, to improve overall patient 
condition.  
RIBA and ELV are antiviral medications whose known action mechanisms do not involve the 
viral protease. ECF similarly than RIBA is a purine analog that interfere with DNA synthesis 
and is used as anticancer treatment. TIC acts as a platelet aggregation inhibitor used for the 
prevention of stroke, heart attack and other events in people with acute coronary syndrome.  
Whereas OTC is a naturally occurring broad spectrum antibiotic produced as secondary 
metabolite by ​Streptomyces​ strains. Chlortetracycline and Doxycycline in Table 1 also 
belong to the same group of antibiotics.  
As indicated by data in Table 1, OTC is the most promising candidate for repositioning as 
SARS-CoV-2 M​pro​ inhibitor. As indicated by the W​QB​ value, a work of at least ~11 kcal/mol is 
required to break main interactions with the oxyanion hole residues and to pull it out from the 
enzyme binding cleft. Moreover, as shown in Figure 5, its W​QB​ profile as a function of H-bond 
distance resemble that of a strong ligand, i.e. with similar outcomes among all DUck 
replicas.  
 
 
 
 
 
 
  
Figure 5​. W​QB​ profile for OTC.  
 
OTC also preserves its original docking pose within M​pro​ binding cleft along the entire 
simulation time in three out of three MD replicas (pose stability in Table 1). Stability of OTC 
binding is also reflected in the complex relative binding free energies (ΔΔG) which has been 
computed with respect to potent alpha-ketoamide inhibitor. For instance, binding of OTC to 
M​pro​ is about  18 kcal/mol more stable than for COD and about 27 kcal/mol than for RIBA 
(see Table 1). Furthermore, binding of potent alpha-ketoamide inhibitor to M​pro​ is just ~12 
kcal/mol more stable than for OTC which is an encouraging result considering the larger size 
of the first one which is a large peptidomimetic inhibitor that target all sub-pocket of M​pro 
binding cleft and it has been specifically designed to bind SARS-CoV-2 M​pro​.​[11] 
 
A more detailed analysis of OTC binding to M​pro  
For a more ​in deep​ analysis of the molecular interactions of OTC at the M​pro​ binding cleft we 
next performed a topological analysis of the charge density (QTAIM) on a representative 
structure from MD simulations.  
Figure 6 shows binding mode of OTC at the SARS-CoV-2 M​pro​ binding cleft. Topological 
elements of the charge density describing OTC interactions are depicted.  
 
 
Figure 6​. Binding mode of OTC at the SARS-CoV-2 M​pro​ binding cleft. Topological elements of the 
charge density are depicted: small red circles are the Bond Critical Points (BCPs) and yellow lines 
connecting them to neighboring nuclei are the Bond Paths (BPs). In A only topological elements for 
the most relevant intermolecular interactions are depicted. While in B all the interactions involving 
OTC are shown to emphasize its extensive anchoring that encompass several binding cleft 
sub-pockets.  
 
Perhaps the most salient characteristic of OTC as potential SARS-CoV-2 M​pro​ inhibitor is its 
overall molecular shape which complements very well the enzyme binding cleft. M​pro​ binding 
cleft is a J-shaped cavity where the S1 and S1’ sub-pockets are perpendicularly oriented to 
S2 and S3 sub-pockets. Thanks to OTC curved shape and size, it can lay over S1 
sub-pocket surface forming an intricate network of interactions with oxyanion hole residues 
Gly143, Ser144 and Cys145 (Figure 6A) and at the same time it can also bind to  
the S2 and S3 sub-pockets which provide additional anchoring points.  
While the overall docking pose is preserved after MD simulations, there have been some 
changes in the interaction pattern that it is worth noting (compare with Figures 3). For 
instance, Glu 166 side chain which was too far as to directly interact with OTC in the docking 
pose, formed a strong H-bond with an OTC hydroxyl group after MD simulations. Also 
interactions at S2/S3 sub-pockets have slightly changed with respect to starting docking 
pose.  
Regarding sub-pocket S2, it is composed by a flat surface as evidenced in Figure 6B. 
However, it has been shown that S2 features substantial plasticity, enabling it to adapt to the 
shape of inhibitor moieties.​[11]​ Potent alpha-ketoamide inhibitor 13b (pdb code 6Y2G) bears a 
cyclopropyl methyl moiety at P2 that fits snugly into the enzyme S2 hydrophobic sub-pocket 
(see reference 11). Unlike 13b, OTC does not target this hydrophobic region of S2 which 
might explain the different shape that S2 adopts and also partially their differences in terms 
of binding affinity.  
  
CONCLUSIONS 
In this work we have performed a virtual screening of FDA approved drugs for repurposing 
as potential inhibitors of SARS-CoV-2 main protease M​pro​.  
Although other studies for drug repositioning as inhibitors of SARS-CoV-2 molecular targets 
have already been reported, they focused mostly in antiviral medications. To our knowledge, 
oxytetracycline, which is the most promising candidate selected in the current virtual 
screening study has not been tested yet, neither in specific M​pro​ inhibitory assays nor in viral 
replication assays. We encourage scientific community working on COVID-19 projects to 
include it (along with the remaining  selected candidates) in their experimental screening 
pipelines.  
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